查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602815

抗體藥物複合體契約製造市場：按連接器、條件和最終用途分類 - 2025-2030 年全球預測

Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

抗體藥物複合體契約製造市場2023年估值為118.8億美元，預計2024年將達到130.6億美元，複合年成長率為11.82%，2030年將達到259億美元，預計將達到9000萬美元。

抗體藥物複合體（ADC）是兼具單株抗體的標靶化能力和細胞毒性藥物的抗癌能力的生物製藥，由於契約製造可以在確保嚴格的品管的同時擴大生產規模，因此特別受歡迎。 ADC 市場需要強大的、有針對性的癌症治療方法，同時對健康細胞的損害最小。應用擴展到各種癌症的治療，包括固體癌和骨髓惡性腫瘤。最終用途範圍主要包括專注於尖端癌症治療的製藥和生物技術公司。市場成長受到連接器技術進步、研發投資增加以及全球癌症發生率上升等因素的影響。政府的支持和擴大已通過核准的ADC 產品組合也正在推動市場發展勢頭。技術創新、拓展新興市場以及共同開發具有更高功效和安全性的下一代 ADC 創造了潛在的商機。最大限度地利用這些機會的研究包括投資研究夥伴關係、擴大服務欠缺地區的製造能力以及開發具有成本效益的 ADC 變體以提高可及性。

主要市場統計
基準年[2023] 118.8億美元
預測年份 [2024] 130.6億美元
預測年份 [2030] 259.9億美元
複合年成長率（%） 11.82%

阻礙市場成長的挑戰包括高昂的開發成本、複雜的製造流程、監管障礙以及對先進專業知識的需求。此外，保持遵守嚴格的法律體制可能會佔用集中資源。創新和研究將提高連接體的穩定性，最佳化有效負載設計以提高療效，同時減少副作用，並開發新型生物標記主導的療法以改善患者分層和治療結果。市場本質上是競爭性的，主要參與者不斷尋求透過產品創新和策略聯盟來實現其產品的差異化。維持強大的管道並適應不斷變化的法規對於成功至關重要。公司應監控技術進步和專利狀況，並積極主動地發現新發現。這種謹慎的態度使我們能夠預測行業變化，並在充滿活力和高度專業化的領域中擁抱新機會。

市場動態：揭示快速發展的抗體藥物複合體契約製造市場的關鍵市場洞察

抗體藥物複合體的契約製造市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 生物製藥公司外包增加
    • CMO 的快速增加和持續的研發活動
    • 慢性病增加導致 ADC 需求增加
  • 市場限制因素
    • 建立抗體藥物複合體生產設施的成本高昂
  • 市場機會
    • ADC 的監管核准迅速增加
    • 擴大先進製造技術投資
  • 市場挑戰
    • 對 CMO 的嚴格監管要求

波特五力：引領抗體藥物複合體契約製造市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗體藥物複合體契約製造市場的外部影響

外部宏觀環境因素在塑造抗體藥物複合體契約製造市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗體藥物複合體契約製造市場的競爭狀況

抗體藥物複合體契約製造市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗體藥物複合體契約製造市場供應商的績效評估

FPNV定位矩陣是評估抗體藥物複合體契約製造市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，描繪抗體藥物複合體契約製造市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對抗體藥物複合體契約製造市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 生物製藥公司外包增加
      • CMO 數量和持續研發活動迅速增加
      • 由於慢性病的流行，對 ADC 的需求增加
    • 抑制因素
      • 建立抗體藥物複合體生產設施的高成本
    • 機會
      • ADC 的監管核准迅速增加
      • 擴大先進製造技術投資
    • 任務
      • 對 CMO 的嚴格監管要求
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章抗體藥物複合體契約製造市場鏈接

  • 可切割
  • 不可切割

第7章依現狀分類的抗體藥物複合體契約製造市場

  • 乳癌
  • 淋巴瘤
  • 骨髓瘤

第8章抗體藥物複合體契約製造市場：依最終用途分類

  • 臨床試驗
  • 骨髓瘤治療

第9章北美和南美抗體藥物複合體契約製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太抗體藥物複合體契約製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：歐洲、中東和非洲抗體藥物複合體的契約製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • ADC Therapeutics SA.
  • AstraZeneca PLC
  • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
  • Axplora
  • Catalent, Inc.
  • Creative Biolabs
  • Daiichi Sankyo
  • EirGenix, Inc.
  • Gilead Sciences
  • GlaxoSmithKline PLC
  • ImmunoGen, Inc.
  • Merck KgaA
  • Mersana Therapeutics
  • MicroBiopharm Japan Co., Ltd.
  • Pfizer Inc.
  • Pierre Fabre SA
  • Piramal Pharma Solutions
  • Recipharm AB
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Biologics
  • Sanofi
  • Sartorius AG
Product Code: MRR-B16853777700

The Antibody Drug Conjugates Contract Manufacturing Market was valued at USD 11.88 billion in 2023, expected to reach USD 13.06 billion in 2024, and is projected to grow at a CAGR of 11.82%, to USD 25.99 billion by 2030.

Antibody Drug Conjugates (ADCs) are biopharmaceuticals that combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, specifically versatile as contract manufacturing facilitates scaling up production while ensuring stringent quality controls. The ADC market is necessary due to its potent and targeted cancer therapies, minimizing damage to healthy cells. Its applications span various oncology treatments, including solid tumors and hematologic malignancies. The end-use scope primarily involves pharmaceutical companies and biotechnology firms focused on cutting-edge cancer treatments. Market growth is influenced by factors such as advancements in linker technology, increased R&D investments, and rising cancer prevalence globally. Government support and an expanding portfolio of approved ADCs also drive market momentum. Potential opportunities arise from technological innovations, expanding into emerging markets, and collaborating on next-generation ADCs with improved efficacy and safety profiles. Recommendations to maximize these opportunities include investing in research partnerships, expanding manufacturing capabilities in underserved regions, and developing cost-effective ADC variants to improve accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 11.88 billion
Estimated Year [2024] USD 13.06 billion
Forecast Year [2030] USD 25.99 billion
CAGR (%) 11.82%

Limitations challenging market growth include high developmental costs, complex manufacturing processes, regulatory hurdles, and the need for highly specialized expertise. Furthermore, maintaining adherence to stringent legal frameworks can be resource-intensive. Innovation and research can focus on improving linker stability, optimizing payload design to enhance efficacy while reducing side effects, and developing novel biomarker-driven therapies that improve patient stratification and treatment outcomes. The market is of competitive nature, with key players continuously seeking to differentiate their offerings through product innovation and strategic collaborations. Maintaining a robust pipeline and adaptability to evolving regulations will be crucial for success. Companies should monitor technological advances and patent landscapes, ensuring proactive engagement with new discoveries. This vigilant approach can anticipate industry shifts and embrace emerging opportunities in a dynamic and highly specialized field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Drug Conjugates Contract Manufacturing Market

The Antibody Drug Conjugates Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing outsourcing by biopharmaceutical companies
    • Surging number of CMOs and ongoing R&D activities
    • Growing demand for ADC amid high prevalence of chronic disease
  • Market Restraints
    • High cost of setting up a production facility for antibody-drug conjugates
  • Market Opportunities
    • Surge in ADC approvals from regulatory bodies
    • Expanding investments in advanced manufacturing technologies
  • Market Challenges
    • Stringent regulatory requirements for CMOs

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Drug Conjugates Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Drug Conjugates Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Drug Conjugates Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Drug Conjugates Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Drug Conjugates Contract Manufacturing Market

A detailed market share analysis in the Antibody Drug Conjugates Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Drug Conjugates Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Drug Conjugates Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibody Drug Conjugates Contract Manufacturing Market

A strategic analysis of the Antibody Drug Conjugates Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugates Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADC Therapeutics SA., AstraZeneca PLC, Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories, Axplora, Catalent, Inc., Creative Biolabs, Daiichi Sankyo, EirGenix, Inc., Gilead Sciences, GlaxoSmithKline PLC, ImmunoGen, Inc., Merck KgaA, Mersana Therapeutics, MicroBiopharm Japan Co., Ltd., Pfizer Inc., Pierre Fabre S.A, Piramal Pharma Solutions, Recipharm AB, Regeneron Pharmaceuticals, Inc., Samsung Biologics, Sanofi, and Sartorius AG.

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugates Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Linker, market is studied across Cleavable and Non-cleavable.
  • Based on Condition, market is studied across Breast Cancer, Lymphoma, and Myeloma.
  • Based on End Use, market is studied across Clinical Trial and Myeloma Treatment.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing outsourcing by biopharmaceutical companies
      • 5.1.1.2. Surging number of CMOs and ongoing R&D activities
      • 5.1.1.3. Growing demand for ADC amid high prevalence of chronic disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of setting up a production facility for antibody-drug conjugates
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in ADC approvals from regulatory bodies
      • 5.1.3.2. Expanding investments in advanced manufacturing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for CMOs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Drug Conjugates Contract Manufacturing Market, by Linker

  • 6.1. Introduction
  • 6.2. Cleavable
  • 6.3. Non-cleavable

7. Antibody Drug Conjugates Contract Manufacturing Market, by Condition

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Lymphoma
  • 7.4. Myeloma

8. Antibody Drug Conjugates Contract Manufacturing Market, by End Use

  • 8.1. Introduction
  • 8.2. Clinical Trial
  • 8.3. Myeloma Treatment

9. Americas Antibody Drug Conjugates Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. ADC Therapeutics SA.
  • 3. AstraZeneca PLC
  • 4. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
  • 5. Axplora
  • 6. Catalent, Inc.
  • 7. Creative Biolabs
  • 8. Daiichi Sankyo
  • 9. EirGenix, Inc.
  • 10. Gilead Sciences
  • 11. GlaxoSmithKline PLC
  • 12. ImmunoGen, Inc.
  • 13. Merck KgaA
  • 14. Mersana Therapeutics
  • 15. MicroBiopharm Japan Co., Ltd.
  • 16. Pfizer Inc.
  • 17. Pierre Fabre S.A
  • 18. Piramal Pharma Solutions
  • 19. Recipharm AB
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Samsung Biologics
  • 22. Sanofi
  • 23. Sartorius AG

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 144. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023